Literature DB >> 20132184

Overexpression of TrkB promotes the progression of colon cancer.

Yingjiao Yu1, Siyang Zhang, Xuemei Wang, Zhiwei Yang, Guocheng Ou.   

Abstract

Studies have confirmed that TrkB plays important roles in facilitating metastasis in various types of malignant tumors. In the present study, 30 cases of colon cancer and matched non-tumors were examined for the expression of TrkB by Western blot. The expression of TrkB was also examined in 90 colon tumor sections by immunohistochemical methods, and D2-40 staining was used to evaluate the correlation between TrkB expression and lymphatic vessel density. To investigate the effects of TrkB on the progression of colon cancer, siRNA specific for TrkB was transfected into LoVo cells, and proliferation, apoptosis and invasion of transfected cells were examined using MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], flow cytometry and Transwell assays, respectively. Our results showed that TrkB was up-regulated in colon tumors compared with the non-tumorous counterparts, and the overexpression of TrkB was closely correlated with lymphatic vessel density (LVD) and metastasis. Inhibition of TrkB by siRNA increased the apoptotic rates of transfected cells, while the numbers of proliferative and invasive cells were decreased. In summary, our data suggest that overexpression of TrkB in colon cancer possibly plays roles in inhibiting apoptosis, promoting proliferation and invasion, facilitating tumor progression by lymphangiogenesis-associated metastasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132184     DOI: 10.1111/j.1600-0463.2009.02577.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  23 in total

1.  TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.

Authors:  Jamie L Croucher; Radhika Iyer; Nanxin Li; Valentina Molteni; Jon Loren; W Perry Gordon; Tove Tuntland; Bo Liu; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-14       Impact factor: 3.333

2.  High TrkB expression levels are associated with poor prognosis and EMT induction in colorectal cancer cells.

Authors:  Hiroyuki Fujikawa; Koji Tanaka; Yuji Toiyama; Susumu Saigusa; Yasuhiro Inoue; Keiichi Uchida; Masato Kusunoki
Journal:  J Gastroenterol       Date:  2012-02-24       Impact factor: 7.527

3.  Methylation and expression patterns of tropomyosin-related kinase genes in different grades of glioma.

Authors:  Mahalakshmi Palani; R Arunkumar; Arrambakam Janardhanam Vanisree
Journal:  Neuromolecular Med       Date:  2014-05-20       Impact factor: 3.843

4.  Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.

Authors:  Mark Merchant; Xiaolei Ma; Henry R Maun; Zhong Zheng; Jing Peng; Mally Romero; Arthur Huang; Nai-ying Yang; Merry Nishimura; Joan Greve; Lydia Santell; Yu-Wen Zhang; Yanli Su; Dafna W Kaufman; Karen L Billeci; Elaine Mai; Barbara Moffat; Amy Lim; Eileen T Duenas; Heidi S Phillips; Hong Xiang; Judy C Young; George F Vande Woude; Mark S Dennis; Dorothea E Reilly; Ralph H Schwall; Melissa A Starovasnik; Robert A Lazarus; Daniel G Yansura
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-23       Impact factor: 11.205

5.  BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin.

Authors:  B T Paul; Z Blanchard; M Ridgway; W M ElShamy
Journal:  Oncogene       Date:  2014-08-18       Impact factor: 9.867

6.  Brain-derived neurotrophic factor/tropomyosin-related kinase B signaling pathway contributes to the aggressive behavior of lung squamous cell carcinoma.

Authors:  Keigo Ozono; Yoshihiro Ohishi; Hideya Onishi; Katsuya Nakamura; Junichi Motoshita; Masato Kato; Ryoichi Nakanishi; Masafumi Nakamura; Yoshinao Oda
Journal:  Lab Invest       Date:  2017-06-12       Impact factor: 5.662

7.  NTRK2 is an oncogene and associated with microRNA-22 regulation in human gastric cancer cell lines.

Authors:  Jinhuai Hu; Yong Huang; Yuanhua Wu; Fengjun Liu; Dong Sun; Kexin Wang; Hui Qu
Journal:  Tumour Biol       Date:  2016-09-23

8.  Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.

Authors:  Radhika Iyer; Lea Wehrmann; Rebecca L Golden; Koumudi Naraparaju; Jamie L Croucher; Suzanne P MacFarland; Peng Guan; Venkatadri Kolla; Ge Wei; Nicholas Cam; Gang Li; Zachary Hornby; Garrett M Brodeur
Journal:  Cancer Lett       Date:  2016-01-18       Impact factor: 8.679

Review 9.  Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer.

Authors:  Hussein Akil; Aurélie Perraud; Marie-Odile Jauberteau; Muriel Mathonnet
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

10.  TrkB expression level correlates with metastatic properties of L1 mouse sarcoma cells cultured in non-adhesive conditions.

Authors:  J Miłoszewska; M Przybyszewska; M Gos; P Swoboda; H Trembacz
Journal:  Cell Prolif       Date:  2013-04       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.